Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Oct 3;13(19):4515-23.
doi: 10.1002/j.1460-2075.1994.tb06773.x.

Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene

Affiliations

Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene

C E Andoniou et al. EMBO J. .

Abstract

v-cbl is the transforming gene of a murine retrovirus which induces pre-B cell lymphomas and myelogenous leukaemias. It encodes 40 kDa of a gag fusion protein which is localized in the cytoplasm and nucleus of infected cells. The c-cbl oncogene encodes a 120 kDa cytoplasmic protein and its overexpression is not associated with tumorigenesis. The c-cbl sequence has shown that v-cbl was generated by a truncation that removed 60% of the C-terminus. In this study, we carried out experiments to identify the position within cbl where the transition occurs between non-tumorigenic and tumorigenic forms. These experiments focused attention on a region of 17 amino acids which is deleted from cbl in the 70Z/3 pre-B lymphoma due to a splice acceptor site mutation. This mutation activates cbl's tumorigenic potential and induces its tyrosine phosphorylation. We also show that the expression of the v-abl and bcr-abl oncogenes results in the induction of cbl tyrosine phosphorylation, and that abl and cbl associate in vivo. These findings demonstrate that tyrosine-phosphorylated cbl promotes tumorigenesis and that cbl is a downstream target of the bcr-abl and v-abl kinases.

PubMed Disclaimer

References

    1. Cancer Res. 1970 Aug;30(8):2213-22 - PubMed
    1. EMBO J. 1993 May;12(5):2017-26 - PubMed
    1. J Immunol. 1978 Aug;121(2):641-7 - PubMed
    1. Cell. 1980 Dec;22(3):777-85 - PubMed
    1. Nature. 1985 Dec 12-18;318(6046):533-8 - PubMed

Publication types

MeSH terms